<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EFA2059D-73E3-4989-9D54-188E5DB50EB6"><gtr:id>EFA2059D-73E3-4989-9D54-188E5DB50EB6</gtr:id><gtr:name>Cepheid</gtr:name><gtr:address><gtr:line1>904 Caribbean Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B67DF9C-9415-470D-8AB8-F670009C904B"><gtr:id>1B67DF9C-9415-470D-8AB8-F670009C904B</gtr:id><gtr:name>Terrence Higgins Trust</gtr:name><gtr:address><gtr:line1>Terrence Higgins Trust</gtr:line1><gtr:line2>314-320 Gray's Inn Road</gtr:line2><gtr:postCode>WC1X 8DP</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D220695F-AA09-4E89-899B-89BB6AD3FFCA"><gtr:id>D220695F-AA09-4E89-899B-89BB6AD3FFCA</gtr:id><gtr:name>Imperial College School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D254125-0806-40E3-A97A-5D9D03D447D7"><gtr:id>9D254125-0806-40E3-A97A-5D9D03D447D7</gtr:id><gtr:name>AIDS Clinical Trials Group (ACTG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EFA2059D-73E3-4989-9D54-188E5DB50EB6"><gtr:id>EFA2059D-73E3-4989-9D54-188E5DB50EB6</gtr:id><gtr:name>Cepheid</gtr:name><gtr:address><gtr:line1>904 Caribbean Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B67DF9C-9415-470D-8AB8-F670009C904B"><gtr:id>1B67DF9C-9415-470D-8AB8-F670009C904B</gtr:id><gtr:name>Terrence Higgins Trust</gtr:name><gtr:address><gtr:line1>Terrence Higgins Trust</gtr:line1><gtr:line2>314-320 Gray's Inn Road</gtr:line2><gtr:postCode>WC1X 8DP</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D220695F-AA09-4E89-899B-89BB6AD3FFCA"><gtr:id>D220695F-AA09-4E89-899B-89BB6AD3FFCA</gtr:id><gtr:name>Imperial College School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D254125-0806-40E3-A97A-5D9D03D447D7"><gtr:id>9D254125-0806-40E3-A97A-5D9D03D447D7</gtr:id><gtr:name>AIDS Clinical Trials Group (ACTG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EAD69D6C-4A04-4567-8945-986175413495"><gtr:id>EAD69D6C-4A04-4567-8945-986175413495</gtr:id><gtr:firstName>Alexander</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Frater</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL006588%2F1"><gtr:id>F91879FF-206F-4BAE-82D2-A244EF241107</gtr:id><gtr:title>MICA: ERADICATE HIV-1: TARGETING THE HIV-1 RESERVOIR WITH NEW IMMUNOTHERAPEUTIC STRATEGIES</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/L006588/1</gtr:grantReference><gtr:abstractText>There is no cure or vaccine for HIV infection. My aim is to explore new strategies for finding a cure for HIV infection. Thirty four million people are estimated to be infected with HIV - nearly 1% of the global adult population. Of these, 8 million are in receipt of antiretroviral therapy (also called 'ART'), but provision of ART to all who need it is a major logistical and financial challenge. Not only do patients have to stay on therapy for the rest of their lives, but there is the risk of drug resistance, side effects and stigma. We are also starting to learn that patients on ART develop other illnesses - such as heart disease, cancers and early dementia - that we do not fully understand. There is a growing understanding that although current HIV therapies have saved millions of lives, sustaining this for the future may demand new strategies. The most challenging of these is to find a cure for HIV.

HIV spreads widely in the human body in the first days after infection. Upon the use of potent ART the amount of residual virus declines dramatically. However, despite many years of continuous treatment the population of infected cells does not disappear completely - there is a 'reservoir' of infected cells. This tiny but dangerous reservoir of cells has the capacity to grow out and restore the original disease state. If all infected cells could be eradicated this would constitute a cure, but this has only been achieved in one individual and involved the radical step of bone marrow transplantation as well as potent chemotherapy - not a solution applicable to the millions of infected people. 

The research will tackle key questions that need to be answered to achieve a cure for HIV. Can we wake up this 'reservoir' of infected cells so that the immune system can attack them? What is the best way to measure the 'reservoir' to assess if a patient might be cured? Are there patients who are more amenable to cure than others - in particular does treatment given very early after infection result in a period of 'remission' in which the patients can stop the drugs without the virus coming back?

The answer to any of these will impact the field significantly. The research will be carried out by Dr John Frater and his team at the University of Oxford, collaborating with researchers across the UK and internationally. The research will be a mixture of laboratory experiments to see how infected cells behave under different conditions and clinical studies in which samples from patients will be tested to try and understand how best to target the reservoir of persisting infected cells.

The studies will be conducted in three related workstreams. In the first, the researchers will study whether cells that contain silenced or 'latent' HIV can be 'woken up' using drugs normally used for cancer and whether the immune system will be able to recognise them. In the second workstream, a new test will be developed for measuring the reservoir using a combination of two techniques - one to measure the amount of viral DNA in the infected cells, and the other to use new genetic technologies to infer whether the viral genes can produce viable replicating viruses. Our aim is to develop and apply the technique, with the potential to bring it into clinical practice. Finally, in the third workstream, the researchers will develop new cohorts of patients treated very early in infection. Early treatment may be a key part of any cure, as the reservoir of infected cells at this stage looks more susceptible to new therapies. By developing these cohorts of adults and children, I aim to provide a platform to do this and conduct tests to see whether a cure might be feasible.

In summary, the research comprises an exciting series of objectives. The need for an HIV cure is great, and if proof-of-principle can be gained in any of these key directions, it would be a major step forward.</gtr:abstractText><gtr:technicalSummary>There is no cure for HIV infection. The strategy of combining agents to activate the HIV viral reservoir in conjunction with immunotherapy is enticing as the most scalable approach to curing HIV. My aims are to prove the basic scientific justification for this strategy, through 3 key objectives: 

1) 'To prove the antigenicity of latently infected cells'. I will expand our data showing that HIV-1 viral protein can be detected in latently-infected resting CD4 T cells, and that the proportion of cells producing protein can be increased using activators of transcription. Using unique immunological reagents - such as affinity-enhanced T cell receptors - I will demonstrate that viral proteins can be presented as antigens, leading to recognition and killing by T cells. 

2) 'To develop and apply new assays for accurate measurement of the HIV-1 viral reservoir'. I will approach the problem that there is no gold standard assay that can be broadly applied to the measurement of the reservoir. I will utilise viral sequence data obtained using deep sequencing to infer the 'replication competent' reservoir. I will develop and apply Qualitative Quantitative PCR ('q2PCR' ) using cell lines, primary cell models and ex vivo patient samples.

3) 'To explore the enhanced potential for viral clearance in patients with Primary HIV-1 Infection (PHI)'. PHI is likely to be a critical time when the reservoir is most susceptible to intervention. Using newly established clinical PHI cohorts, I will explore how antiretroviral therapy (ART) when given in PHI - potentially in combination with other agents - might impact viral control and induce a state of remission, or 'post-treatment control'. Understanding PHI - and the impact of ART - would have a major bearing on strategies for eradicating HIV, and for guidelines on improved screening for patients. 

The work will be undertaken at a centre with a world-class record in HIV immunology and in collaboration with industry partners.</gtr:technicalSummary><gtr:potentialImpactText>In the long-term, the research has the potential to impact at the global level, however I will also address the importance of the short- and medium-term objectives. The impact of a cure for HIV on patients, at-risk groups, health-care providers, policy makers, society and governments is clearly enormous. It is the landscape-changing nature of such an achievement that justifies (and demands) undertaking potentially high-risk research. There is a demand for such research from patient groups and representatives (Simon Collins, director of the major patient treatment activist group, i-base, sits on the steering committee of CHERUB) as well as from government (I presented on HIV Cure at a recent Department of Health workshop with the Chief Medical Officer, Dame Sally Davies).

A cure that is applicable to populations still remains years away. However, the proof of concept studies suggested in this proposal are critical and will impact the field and 'users' through the incremental steps in knowledge, methods and process that are required for such an undertaking.

There are 34 million people infected with HIV globally. In the UK around 100,000 individuals are HIV positive and rates of new infection are on the increase again. A cure for these users would allow patients to stop therapy, avoiding the risks of toxicity, drug resistance, stigmatisation and treatment fatigue that can lead to new transmissions and patient morbidity. The wider publicity attracted by cure research also has the impact of maintaining public awareness of HIV infection with the potential for safer sex practices and reduced transmission rates.

HIV costs the National Health Service approximately &amp;pound;1 billion per year. A cure has the potential to confer significant savings, although this will only be proven once the costs of any new treatments are clear.

In the shorter term, this Fellowship will be conducted in collaborations with Merck, Gilead and Adaptimmune, under fully executed Material Transfer Agrements. The commercial potential for using adapted TCRs (Adaptimmune) to target latently infected cells are significant, as are the applications of the drugs Vorinostat (Merck) and Romidepsin (Gilead) for HIV infection.

The development and validation of the q2PCR assay for reservoir quantification has commercial potential in clinical practice as well as the for the development of new bioinformatic pipelines for the analysis of deep-sequencing data and its incorporation into a clinical assay.

The discovery of new antigenic targets on latently infected cells has the potential to impact the HIV vaccine field. I already work closely with academic collaborators in Oxford (Hanke, Dorrell) and Okairos, with an application to the MRC for the REACH trial (under final review), the first proof-of-concept study of HDAC inhibitors plus vaccination in HIV infection. If vaccines can be used to target activated latent cells, this has the potential to open a new direction for HIV vaccination.

The studies of the new cohorts (HEATHER, RESPECT), as well as the already recruited SPARTAC cohort, will potentially impact treatment guidelines and strategies for assaying patients on therapy. If treatment in very early PHI can impact the reservoir and induce a state of 'post-treatment control' (as now suggested in a number of reports), confirmation of this in structured cohorts would impact screening programs to identify patients close to seroconversion, treatment guidelines to start ART as early as possible and assay development to measure the reservoirs (or other yet to be determined markers) in patients with possible induced control, and further assays (eg home testing) to allow regular monitoring of patients off therapy for virological rebound.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-09-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1468100</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>Agreement with RHS for an HIV garden to be presented at the 2018 Chelsea flower show in collaboration with Terrence Higgins Trust to improve engagement with public around issues associated with living with HIV and how research is improving outcomes</gtr:description><gtr:id>BCDC31CD-6304-4BCE-ABE1-4CC289A157E7</gtr:id><gtr:impact>On-going</gtr:impact><gtr:outcomeId>58c194c3432069.83049317</gtr:outcomeId><gtr:title>RHS Chelsea Royal Flower Show - HIV Garden</gtr:title><gtr:type>Artistic/Creative Exhibition</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Emerging Infections</gtr:department><gtr:description>Oxford Martin School</gtr:description><gtr:id>0AE98F77-40E7-4D3B-95C7-AF89B1A1B25D</gtr:id><gtr:impact>Multiple publications (see bibliography)
New research proposals</gtr:impact><gtr:outcomeId>58c173f6b70207.61415317-1</gtr:outcomeId><gtr:partnerContribution>Our partners bring bioinformatic expertise and mathematical modelling</gtr:partnerContribution><gtr:piContribution>Our research contributes bioinformatics and next generation sequencing analyses to answer questions around viral persistence. In my own group's case this is HIV, but the institute covers other pathogens such as HCV and HBV.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>James Martin 21st Century School</gtr:department><gtr:description>Oxford Martin School</gtr:description><gtr:id>441F12F2-1D49-4404-9333-5032B7CBD5DE</gtr:id><gtr:impact>On-going publications from Institute of Emerging Infections, documented in publications section of portfolio</gtr:impact><gtr:outcomeId>LAPugUtGLK7-1</gtr:outcomeId><gtr:partnerContribution>Development of software pipelines and sequencing technologies to inform HIV and HCV cure strategies</gtr:partnerContribution><gtr:piContribution>Collaboration stemming from the Institute of Emerging Infection and resulting in a new round of funding won through a competitive process</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Thomas' Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HEATHER Cohort</gtr:description><gtr:id>12B50D33-962C-43EC-A453-DC1365C118C7</gtr:id><gtr:impact>Recruitment of patients
Sample repository in Oxford
Public engagement meetings
Oral abstract presentation at national and international meetings</gtr:impact><gtr:outcomeId>56dc59e352ff95.07219850-2</gtr:outcomeId><gtr:partnerContribution>Identification, recruitment and sampling of patients</gtr:partnerContribution><gtr:piContribution>Collaboration to recruit patients to a new cohort of patients with primary HIV infection</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cepheid</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cepheid Inc</gtr:description><gtr:id>ACE98144-531B-4047-988A-75D764218219</gtr:id><gtr:impact>Abstract submitted to international meeting
Further projects developed</gtr:impact><gtr:outcomeId>58c17480b28470.42200056-1</gtr:outcomeId><gtr:partnerContribution>Provision of equipment and training</gtr:partnerContribution><gtr:piContribution>Testing of new diagnostics for point of care HIV monitoring</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Physical and Theoretical Chemistry Laboratory</gtr:department><gtr:description>Dept Of Physical Chemistry, University of Oxford</gtr:description><gtr:id>F94335C4-F80A-43D5-B70F-DFBFBEACB3C1</gtr:id><gtr:impact>CIC Funding
UCSF funding
Patents pending</gtr:impact><gtr:outcomeId>58c15fbff36d43.91377134-1</gtr:outcomeId><gtr:partnerContribution>Partners bring expertise in microfluidics</gtr:partnerContribution><gtr:piContribution>Research collaboration to develop microfluidic diagnostic platforms. Awarded MRC CiC grant and UCSF award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>PITCH cohort</gtr:description><gtr:id>C038D04A-3FC7-442A-B3C4-EAFBDA181B7D</gtr:id><gtr:impact>Multi-disciplinary: GU medicine plus immunology and virology
Ethical and HRA approvals received</gtr:impact><gtr:outcomeId>58c160bc7a8b27.48866463-1</gtr:outcomeId><gtr:partnerContribution>Recruitment of patients to the PITCH study</gtr:partnerContribution><gtr:piContribution>Collaborative team from Oxford, Cambridge, Imperial, UCL and King's. We provide trial protocol and sponsorship as well as assay platforms for sample analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HEATHER Cohort</gtr:description><gtr:id>03C49106-CBA2-4B4E-A659-22525A9564C0</gtr:id><gtr:impact>Recruitment of patients
Sample repository in Oxford
Public engagement meetings
Oral abstract presentation at national and international meetings</gtr:impact><gtr:outcomeId>56dc59e352ff95.07219850-3</gtr:outcomeId><gtr:partnerContribution>Identification, recruitment and sampling of patients</gtr:partnerContribution><gtr:piContribution>Collaboration to recruit patients to a new cohort of patients with primary HIV infection</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AIDS Clinical Trials Group (ACTG)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>AIDS Clinical Trials Group</gtr:description><gtr:id>750F40E9-902B-4B6B-9876-15F4BF050B57</gtr:id><gtr:impact>Sharing of data - multidisciplinary - virology/immunology/epidemiology/mathematical modelliing</gtr:impact><gtr:outcomeId>58c159fdb4d326.22228410-1</gtr:outcomeId><gtr:partnerContribution>Monthly teleconferences to allow sharing of information and unpublished data to inform further research</gtr:partnerContribution><gtr:piContribution>UK representative of US ACTG HIV Cure strategy committee. Role is to explore new treatment strategies and studies, and to explore potential funding options.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Terrence Higgins Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Terrence Higgins Trust</gtr:description><gtr:id>CFCBA49D-F283-43AF-93CE-BE1362331EEF</gtr:id><gtr:impact>Plans approved by RHS</gtr:impact><gtr:outcomeId>58c165a1ec1d08.96485049-1</gtr:outcomeId><gtr:partnerContribution>Engagement with potential donors and direct support for the project</gtr:partnerContribution><gtr:piContribution>Presentation and development of ideas for a public engagement project at RHS Chelsea</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College School of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HEATHER Cohort</gtr:description><gtr:id>1BD5AB68-D8CA-4E4C-884A-4F54EBEC4B90</gtr:id><gtr:impact>Recruitment of patients
Sample repository in Oxford
Public engagement meetings
Oral abstract presentation at national and international meetings</gtr:impact><gtr:outcomeId>56dc59e352ff95.07219850-1</gtr:outcomeId><gtr:partnerContribution>Identification, recruitment and sampling of patients</gtr:partnerContribution><gtr:piContribution>Collaboration to recruit patients to a new cohort of patients with primary HIV infection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Exhibit at Science Museum, London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A8C053D2-BE3A-4B15-97E1-24C77E3477FC</gtr:id><gtr:impact>Display at Science Museum in London on CHERUB, its research outputs and prospects for an HIV Cure</gtr:impact><gtr:outcomeId>56dc7c86841f81.05065053</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cherub.uk.net</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1A4FA578-F7B4-4901-954A-715F04C07BBF</gtr:id><gtr:impact>Stand for NDM on HIV Cure at Cheltenham Science Festival</gtr:impact><gtr:outcomeId>56dc7cd66590f8.09573051</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.cherub.uk.net</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RHS Chelsea HIV Garden - proposal accepted for 2018</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2D6FB5AC-67C8-4F0A-80CB-356EE75F6253</gtr:id><gtr:impact>Proposal submitted to RHS for a garden dedicated to HIV therapy and cure for the 2018 Flower Show. Proposal accepted and work has commenced to raise funding</gtr:impact><gtr:outcomeId>58c1652b284651.82844492</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HEATHER participant meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0C6D061D-7351-4233-AB67-A54E73FF5D42</gtr:id><gtr:impact>Patient group meeting at Imperial College for HEATHER cohort</gtr:impact><gtr:outcomeId>56e0548b2f46c1.50910199</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L006588/1</gtr:fundingRef><gtr:id>5E5A1160-F7FE-4AE8-8656-B92E6A5B0A3E</gtr:id><gtr:outcomeId>54631f48b410b2.30720457</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66647</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CiC</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>83300916-F656-4D73-B8CA-03BF3C161E23</gtr:id><gtr:outcomeId>58c163b187b447.65040444</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>107333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Nuffield Dept of Medicine Studentship (for GM)</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>1E5CBD40-0AAD-413C-9C0C-135539BA9723</gtr:id><gtr:outcomeId>56dc5c59837ad5.72260536</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66497</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCSF</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Oxford Innovation Ltd</gtr:fundingOrg><gtr:id>6603FE05-2D11-44D2-BAFB-1C97DEE1FDA7</gtr:id><gtr:outcomeId>58c1635a4f6e36.40535447</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450593</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>073BA9F0-53FA-4973-B578-83EF64DE2B40</gtr:id><gtr:outcomeId>58c163034ceb24.32543369</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>264635</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship (for JT)</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0C5EFDBA-B192-4CFE-B327-2E905B1852AF</gtr:id><gtr:outcomeId>56dc5ba5ccb2b2.34791653</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L00528X/1</gtr:fundingRef><gtr:id>1CA67C37-9A36-49D8-869D-FD6CFFDE912E</gtr:id><gtr:outcomeId>W6zwXHyDe9z</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>86000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Nuffield Dept of Medicine Studentship (for MJ)</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>34E2A0EE-FF9A-4394-8AB7-A916A70623AA</gtr:id><gtr:outcomeId>56dc5cfe61bb54.20572851</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British HIV Association treatment guidelines 2015</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>British HIV Association treatment guidelines</gtr:guidelineTitle><gtr:id>04EC742A-3440-43D4-8FF6-588AFB5F3C70</gtr:id><gtr:outcomeId>56dc9e0f3dfcd1.97249069</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.bhiva.org</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Engagement with iBase</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B026F5CB-1AE3-4AAD-BC80-BC1773111483</gtr:id><gtr:impact>PAtient and public education around HIV from the ibase publication, website and Twitter feed</gtr:impact><gtr:outcomeId>ZCfnJg7jY3E</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Collection of data regarding participants in the HEATHER HIV cohort</gtr:description><gtr:id>21EABD77-8838-418F-A000-5E7F2BD91C95</gtr:id><gtr:impact>NIl as yet. Research protocols deriving from the database in preparation</gtr:impact><gtr:outcomeId>56dca2f146f961.51551418</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HEATHER database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Samples of PBMCs and plasma from 250 patients with primary HIV infection</gtr:description><gtr:id>CFC350D3-9392-485C-BB2F-A9A8AEF8A06C</gtr:id><gtr:impact>Pending analysis</gtr:impact><gtr:outcomeId>56dca0234b1586.66605575</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HEATHER sample repository</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Assay developed to microfluidic droplets to enrich and sort very rare cell populations</gtr:description><gtr:id>9E815888-1104-4A10-9171-9B77E8914085</gtr:id><gtr:impact>Working with Physical Chemistry this method is being optimised for clinical application.
Patents currently being applied for</gtr:impact><gtr:outcomeId>58c191e9a43337.76726903</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Microfluidic sorting</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Application of sureselect enrichment to rare DNA integrants in clinical samples</gtr:description><gtr:id>D1832629-782C-4951-BA09-5B5A955E9505</gtr:id><gtr:impact>The SOP for this method will be made available following publication
This technique allows next gen sequencing of rare proviral HIV sequences - currently not possible consistently using present methodology
Manuscript in preparation</gtr:impact><gtr:outcomeId>58c191822fb580.36871194</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Sequencing bioinformatics</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A7A77B34-18FB-460C-9E2E-934B611156A2</gtr:id><gtr:title>Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cc35c67f1f89bfab8c3f77b00113a5"><gtr:id>17cc35c67f1f89bfab8c3f77b00113a5</gtr:id><gtr:otherNames>Payne RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54631c13ad5fb1.63085924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73E1256B-4282-47E7-AA08-DE2AECF4C82B</gtr:id><gtr:title>HIV-1 DNA predicts disease progression and post-treatment virological control.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d110ea42909082884b279ca15d700684"><gtr:id>d110ea42909082884b279ca15d700684</gtr:id><gtr:otherNames>Williams JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>54631c13176571.02854141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83FC503F-8A89-42B1-83BF-7098E3FA77D8</gtr:id><gtr:title>Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports.</gtr:title><gtr:parentPublicationTitle>Infectious diseases and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd93323ca1f87347a200b0499bfb0deb"><gtr:id>bd93323ca1f87347a200b0499bfb0deb</gtr:id><gtr:otherNames>Fox J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2193-6382</gtr:issn><gtr:outcomeId>56dc54731f60c7.26335622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D544F9-B01F-4FB4-87E3-720D5CFE802C</gtr:id><gtr:title>Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef922613a50f9dbe25b1e6f369d66d77"><gtr:id>ef922613a50f9dbe25b1e6f369d66d77</gtr:id><gtr:otherNames>Martin GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c158017db1a4.89697761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18478835-295A-4AC3-ABB9-EACB3D4286DD</gtr:id><gtr:title>Evaluation of a novel automated volumetric flow cytometer for absolute CD4+ T lymphocyte quantitation.</gtr:title><gtr:parentPublicationTitle>Cytometry. Part B, Clinical cytometry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/537bebfc51dc2ce357754d45870444a2"><gtr:id>537bebfc51dc2ce357754d45870444a2</gtr:id><gtr:otherNames>Gossez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1552-4949</gtr:issn><gtr:outcomeId>56dc5472f066d2.12887877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>570BFB03-4DD2-4FAC-8DED-0A7CCBD04096</gtr:id><gtr:title>Impact of pre-adapted HIV transmission.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/341e8375fd0b70edf6a5b6519cee6d87"><gtr:id>341e8375fd0b70edf6a5b6519cee6d87</gtr:id><gtr:otherNames>Carlson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>58c15802e92c28.80634752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F79D8580-521A-4BD3-B63A-23360C2E0724</gtr:id><gtr:title>A contaminant-free assessment of Endogenous Retroviral RNA in human plasma.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc445509ec401db71d2ef6fc06e00646"><gtr:id>dc445509ec401db71d2ef6fc06e00646</gtr:id><gtr:otherNames>Karamitros T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c158028d8d57.38477138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A954385F-0BAE-4BA5-AD87-F3DE6FB12FD0</gtr:id><gtr:title>The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0422310b7b85faad60b4329c6ae24ec2"><gtr:id>0422310b7b85faad60b4329c6ae24ec2</gtr:id><gtr:otherNames>Thornhill JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58c1580153ea56.36969317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>219034EB-53C2-4FED-845C-508FE20EFB81</gtr:id><gtr:title>Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17f561bb54c2cb889420f73cc138ae78"><gtr:id>17f561bb54c2cb889420f73cc138ae78</gtr:id><gtr:otherNames>Muenchhoff M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>58c158025d2871.45925598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DD1B7DA-9D6A-4635-A992-92001813D119</gtr:id><gtr:title>Structured observations reveal slow HIV-1 CTL escape.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b3a1a51c3002305d7f4b6e5412f23a"><gtr:id>47b3a1a51c3002305d7f4b6e5412f23a</gtr:id><gtr:otherNames>Roberts HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56dc547496dce8.12777390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92147D80-6F84-41B6-A493-267DB0AEDF1F</gtr:id><gtr:title>The impact of immunoglobulin in acute HIV infection on the HIV reservoir: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/468a1f21b90b1ce6a3f01ffd8194de8e"><gtr:id>468a1f21b90b1ce6a3f01ffd8194de8e</gtr:id><gtr:otherNames>Tiraboschi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a9fa8fc5e71d1.26441992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9A9D576-5CFA-410D-882E-589B9842D604</gtr:id><gtr:title>Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0388d82e28eafdc37c760343c1f26c30"><gtr:id>0388d82e28eafdc37c760343c1f26c30</gtr:id><gtr:otherNames>Hoehn KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>56dc5473800c12.05494881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC13AF64-4E1D-4B2B-8E79-77D09B6E61F2</gtr:id><gtr:title>Differential Immunodominance Hierarchy of CD8T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81959f2a0b1cc2014169164ebdc5f383"><gtr:id>81959f2a0b1cc2014169164ebdc5f383</gtr:id><gtr:otherNames>Adland E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a9fa8b8b37229.48925060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3543AFEC-6CA3-4B0F-8801-412F07A90899</gtr:id><gtr:title>Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90125481fb4dfc3fbc189fb40e3fb70f"><gtr:id>90125481fb4dfc3fbc189fb40e3fb70f</gtr:id><gtr:otherNames>Davies O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>56dc5474ebadc6.50799917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C66E8852-5A44-4519-A4D5-F32AEA6FC57E</gtr:id><gtr:title>High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5706f9c76e406abe3c614f09d311abc1"><gtr:id>5706f9c76e406abe3c614f09d311abc1</gtr:id><gtr:otherNames>Duncan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>54631c13d1ad34.18429042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93D966D4-7C05-417F-9000-4B3ACB16E1ED</gtr:id><gtr:title>Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beb552bb58d9b68654f8911bcd7927a3"><gtr:id>beb552bb58d9b68654f8911bcd7927a3</gtr:id><gtr:otherNames>Pace M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>58c15802b9e3e4.01707459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>433FDA39-8E76-4714-85AA-3226E0E3EDCF</gtr:id><gtr:title>Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fd3d6b237a769e709489e85aafbce8f"><gtr:id>5fd3d6b237a769e709489e85aafbce8f</gtr:id><gtr:otherNames>Payne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56dc547520f878.57126233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CA3C996-5CF0-48E8-B9FE-435278C10691</gtr:id><gtr:title>Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54631c14069e30.67403351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>298DCF9F-3720-43B8-A557-1AAF942FE0E7</gtr:id><gtr:title>Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81959f2a0b1cc2014169164ebdc5f383"><gtr:id>81959f2a0b1cc2014169164ebdc5f383</gtr:id><gtr:otherNames>Adland E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56dc5473e8f8d6.97831310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6085C876-DBA1-40B3-A1E3-B05843E47B56</gtr:id><gtr:title>The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56dc5474257764.02412280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009DDD32-A65A-4D09-9BCE-D210D9D218CE</gtr:id><gtr:title>Advancing the HIV cure agenda: the next 5 years.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>56dc5474c7d213.47009261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>697AD47A-C5C8-4473-BAA1-BE4551120A5D</gtr:id><gtr:title>A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a6f2d88267379.20570966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1507000-87E8-44C4-B786-6FB069708410</gtr:id><gtr:title>Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c15801e0fef0.67710598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CFAE8AA-2206-415D-B7D8-3CEE5B9C9B6C</gtr:id><gtr:title>Thirty years of treating HIV-1 infection: where next?</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934ccb890f8b3d4435bbe06cfa0daeeb"><gtr:id>934ccb890f8b3d4435bbe06cfa0daeeb</gtr:id><gtr:otherNames>Frater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn><gtr:outcomeId>56dc547469d777.30225497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9B867A1-5B19-400E-A4B9-345F45CC80DF</gtr:id><gtr:title>Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, 'definetherain'.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f960dc64663392005f3fbcba53da956"><gtr:id>9f960dc64663392005f3fbcba53da956</gtr:id><gtr:otherNames>Jones M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>54631c1389efe7.00519309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>180F52E9-97F8-4DF0-AC2C-CE97F3E3E04B</gtr:id><gtr:title>Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89a540d6c751925507b99f59b9059109"><gtr:id>89a540d6c751925507b99f59b9059109</gtr:id><gtr:otherNames>Hurst T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>56dc5472c3c122.35109415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E751342E-8F0F-4CF7-8892-388B358F2B81</gtr:id><gtr:title>Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0966c26065499e9ac524eee2d2518f5d"><gtr:id>0966c26065499e9ac524eee2d2518f5d</gtr:id><gtr:otherNames>Hoffmann M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>585d3f842b9257.92086594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69E51275-D8A4-4CB2-AC68-4C4FDAB71978</gtr:id><gtr:title>Early antiretroviral therapy reduces HIV DNA following perinatal HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a6f2e56c9da32.62659945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBD0ADB8-5143-4647-9544-4386EE07C46A</gtr:id><gtr:title>A cure for HIV: is it in sight?</gtr:title><gtr:parentPublicationTitle>Expert review of anti-infective therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beb552bb58d9b68654f8911bcd7927a3"><gtr:id>beb552bb58d9b68654f8911bcd7927a3</gtr:id><gtr:otherNames>Pace M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-7210</gtr:issn><gtr:outcomeId>54631c13656a64.89782110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>351FA45C-8985-4DD0-AB50-B739BAB29BC5</gtr:id><gtr:title>Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5447a20e5237a088883e190d3b9dae"><gtr:id>5e5447a20e5237a088883e190d3b9dae</gtr:id><gtr:otherNames>Bonsall D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>5a6f2d4c9333e3.62854949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D827EFC-DD63-4346-9945-749988DE771B</gtr:id><gtr:title>Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/468a1f21b90b1ce6a3f01ffd8194de8e"><gtr:id>468a1f21b90b1ce6a3f01ffd8194de8e</gtr:id><gtr:otherNames>Tiraboschi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>58c15801b1d2f4.10895520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CD81E4D-B480-4227-AF9D-DF3CCC88A4B2</gtr:id><gtr:title>Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8ec98240adbc03a6bc8db72fed0b1d8"><gtr:id>d8ec98240adbc03a6bc8db72fed0b1d8</gtr:id><gtr:otherNames>Hurst J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56dc54734d0c08.47695811</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L006588/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>